There is increasing evidence for the role of wild-type p53 induced phosphatase 1 (Wip1) phosphatase in the regulation of tumorigenesis. To evaluate Wip1 as a breast cancer oncogene, we generated a mouse strain with targeted expression of Wip1 to the breast epithelium. We found that these mice are prone to cancer when intercrossed with transgenics expressing the ErbB2 oncogene but not conditional knockouts for Brca2. This tumor-prone phenotype of Wip1 is fully eliminated through attenuation of proliferation by activating the MKK6/p38 mitogenactivated protein kinases (MAPK) cascade in mice bearing a constitutively active form of MKK6. We propose that Wip1 phosphatase operates within the MKK6/p38 MAPK signaling pathway to promote ErbB2-driven mammary gland tumorigenesis.
The protein phosphatase wild-type p53 induced phosphatase 1 (Wip1) was identified using differential display methodology and its expression was found to be regulated in a p53-dependent manner (Fiscella et al., 1997) . Wip1 mRNA is rapidly induced by ionizing radiation in wild-type but not in p53-deficient cells confirming its regulation by p53 after genotoxic stress (hence the name, wild-type p53 induced phosphatase 1) (Fiscella et al., 1997) . Further analysis of transcriptional regulation, however, revealed that Wip1 could also be activated through p38 mitogen-activated protein kinases (MAPK) raising the possibility of Wip1 regulation independent of p53 (Takekawa et al., 2000) .
Through a combination of genetic and molecular studies, it was established that Wip1 functions in a linear pathway with p53 (Bulavin et al., 2002; Li et al., 2002) . A large majority of primary breast tumors that overexpress Wip1 have a structurally intact p53 gene, implying that Wip1 may contribute to the functional inactivation of p53 (Bulavin et al., 2002; Rauta et al., 2006) . Further evidence with a rodent fibroblast transformation assay showed that introduction of Wip1 along with Ras, Myc, or ErbB2 resulted in enhanced colony formation in soft agar and led to the development of tumors when these cells were explanted into nude mice (Bulavin et al., 2002) . These findings suggested that Wip1 phosphatase has oncogenic potential (Bulavin et al., 2002; Li et al., 2002; Hirasawa et al., 2003; Saito-Ohara et al., 2003) .
Human Wip1 is encoded by the protein phosphatase magnesium dependent 1 delta (PPM1D) gene, which was mapped to chromosome 17q22-23. This site has been found to be a hot spot for gene amplifications in multiple types of human cancer. The initial observation of regional gain at chromosome 17q22-23 using a comparative genomic hybridization (CGH) technique detected amplification in B18% of primary breast tumors (Kallioniemi et al., 1994) , giving its name to the locus as the 17q23 breast cancer amplicon. Three potential oncogenes, RPS6KB1, TBX-2 and WIP1 have been found within this genomic locus at chromosome 17q22-23 (Sinclair et al., 2003) . However, it remains uncertain whether any of these oncogenes can induce mammary gland tumors when overexpressed in mice.
To investigate the role of Wip1 phosphatase in the regulation of tumorigenesis under in vivo conditions, we generated transgenic mice in which the expression of Wip1 was targeted to the mammary gland epithelium by the mouse mammary tumor virus (MMTV) promoter. Eighteen female founders were generated and analyzed for expression of Wip1. As shown in Figure 1a , Wip1 was expressed at high levels in MMTV-PPM1D mammary gland epithelia compared to wild-type tissues, however, the level of expression varied between different founders. For analysis we used only female mice and kept all females as virgins throughout the entire observation period. All female founders were monitored by palpation twice weekly for development of mammary gland tumors over a 2-year period and two founders were chosen for further in depth analysis based on their level of Wip1 expression: #619 (medium level (B8-fold by RNA dot-hybridization) of Wip1 overexpression) and #676 (high level (B20-fold) of Wip1 overexpression) (Figure 1a) . Overexpression of Wip1 showed no abnormal overt phenotype on development, lactation or involution of mouse mammary glands (data not shown). Analysis of the spontaneous tumor formation revealed that none of the 18 female founders expressing MMTV-PPM1D developed mammary tumors within 2 years. This suggested that overexpression of Wip1 phosphatase alone is not sufficient to cause breast cancer in mice. This data is in agreement with previously published results showing that Wip1 is a weak oncogene. However, Wip1 can complement in vitro other oncogenes, such as Ras and ErbB2, in their ability to transform mouse embryo fibroblasts, yet with low efficiency (Bulavin et al., 2002) . To understand whether Wip1 phosphatase can cooperate with other oncogenes in promoting tumorigenesis in vivo, we crossed MMTV-PPM1D mice with mice expressing an MMTV-ErbB2 transgene. Analysis of tumor onset in a cohort of littermates obtained from these crosses revealed that MMTV-ErbB2/PPM1D double transgenic mice showed an accelerated rate of onset of mammary gland tumors when compared to MMTV-ErbB2 mice (Figure 1b) . While Wip1 overexpression complemented the ErbB2 oncogene in the development of mammary gland tumors, we observed no cooperative effect with Brca2 conditional knockouts (Table 1; Jonkers et al., 2001) . Only 14.3% of Brca2 knockouts developed mammary gland tumors within 2 years, which was similar to the incidence of tumors in Brca2 knockouts expressing MMTV-PPM1D (10.7%). Similar results were obtained for both MMTV-PPM1D founders that were used in this study.
Although early onset of breast cancer could possibly result from an increase in oncogene expression, our analysis did not reveal any difference in ErbB2 levels in normal and tumor samples obtained from MMTVErbB2 and MMTV-ErbB2/PPM1D mice (data not shown). Previous analysis showed that Wip1 could modulate apoptotic response and proliferation (Bulavin et al., 2004; Belova et al., 2005) , which could explain the early onset of tumors observed in MMTV-ErbB2/ PPM1D mice. While there was no significant difference in the rate of apoptosis between analyzed samples Several potential downstream targets of Wip1 have been identified in vitro: p38 MAPK, p53, Chk1, Chk2 and ataxia-telangiectasia mutated (ATM) (Takekawa et al., 2000; Lu et al., 2005; Fujimoto et al., 2006; Shreeram et al., 2006) . The role of p38 MAPK is particularly interesting, as we previously found that Wip1-deficient mice show a p38 MAPK-dependent delay in the onset of breast cancer when crossed with MMTV-ErbB2 transgenic mice (Bulavin et al., 2004) . To systematically address the significance of the p38 MAPK signaling pathway in regulation of tumorigenesis by Wip1 phosphatase, we next generated transgenic mice expressing a constitutively active form of MKK6 kinase, an upstream regulator of p38 MAPK (Raingeaud et al., 1996) . Our rationale was that if Wip1 overexpression accelerates tumorigenesis in MMTV-ErbB2 mice through deregulation of the MKK6-p38 MAPK signaling pathway, its activation in MMTV-MKK6 mice should mitigate such an effect. Several founders were generated and two of them were analyzed for expression of MKK6. Expression was increased (B2.5-times) in the mammary gland tissues but not in the spleen of MMTV-MKK6 transgenics (Figure 2a Figure 2b ). Analysis of mice expressing MKK6 showed no abnormal overt phenotype on development, lactation or involution of mouse mammary glands (data not shown). We next crossed MMTV-MKK6 mice with MMTV-ErbB2 mice and analyzed the littermates for development of breast tumors. We found that while there was a trend in delaying the tumor onset in MMTV-ErbB2/MKK6 females, it was not significantly different from MMTV-ErbB2 mice (Figure 2c) . These results were different from the effect of Wip1 ablation on a delay in tumor formation in MMTV-ErbB2 mice (Bulavin et al., 2004) . To understand the potential reason for such a discrepancy, we analyzed the effect of MKK6 overexpression on the level of endogenous Wip1 in MMTV-MKK6 transgenics. It was previously shown that the MKK6/p38 MAPK-dependent signaling pathway could efficiently upregulate Wip1 expression (Takekawa et al., 2000) . Analysis of Wip1 mRNA expression by real-time polymerase chain reaction (PCR) revealed that breast epithelia from MMTV-MKK6 females contained B2.5 more Wip1 mRNA compared to wild-type mice (Figure 2d ). Thus, increased levels of endogenous Wip1 could be a factor that diminishes the tumor-suppressive function of MKK6 in vivo.
Although we did not observe any effect of MKK6 on delaying the onset of mammary gland tumors in MMTV-ErbB2/MKK6 mice (Figure 3a) , we asked whether activation of the MKK6/p38 MAPK signaling pathway could revert the tumor-prone phenotype in MMTV-PPM1D transgenics. Next, we intercrossed mice expressing Wip1, MKK6 and ErbB2 and analyzed littermates for mammary tumor formation. We found that the onset of mammary gland tumors was reverted in triple MMTV-ErbB2/PPM1D/MKK6 transgenics compared to MMTV-ErbB2/PPM1D mice (Figure 3a) . Wip1 phosphatase in breast cancer ON Demidov et al (Bulavin et al., 2002 (Bulavin et al., , 2004 . We previously found that activation of p38 MAPK could be critical in rendering Wip1-deficient mice resistant to mammary gland tumors driven by ErbB2 (Bulavin et al., 2004) . Further studies revealed that in addition to p38 MAPK and despite the substrate preference toward the pTXpY sequence (Yamaguchi et al., 2005) , Wip1 could also efficiently dephosphorylate critical serine residues on p53, Chk1 and Chk2 in vitro (Lu et al., 2005; Fujimoto et al., 2006; Shreeram et al., 2006) . Likewise, Wip1 phosphatase plays an important role in dephosphorylating ATM both in vitro and in vivo and in the regulation of ATM's ability to attenuate myc-driven lymphomagenesis (Shreeram et al., 2006; Shreeram et al., submitted) . Thus, although we expected to see a substantial tumorprone phenotype in MMTV-PPM1D transgenic mice, they actually remained tumor-free. This further supports the notion that Wip1 behaves as a modulator of tumorigenesis and a weak oncogene in vivo (Bulavin et al., 2002; Li et al., 2002) . Wip1 overexpression using an MMTV promoter does not have any overt effect on mammary gland development. However, the onset of breast tumors in mice expressing MMTV-ErbB2 is accelerated and the activation of the MKK6/p38 MAPK signaling pathway mitigates this phenotype (Figure 1b and 3a) . These data are consistent with the role of p38 MAPK in ErbB2-dependent activation of p21 Waf1 and suppression of proliferation which could be efficiently reversed by inactivation of p38 MAPK (Trost et al., 2005) .
In contrast to the activation of MKK6 in vitro, which is sufficient to reduce tumor growth of HeLa cells explanted into nude mice (Timofeev et al., 2005) , in vivo MKK6 does not have a strong effect on suppression of tumor onset in MMTV-ErbB2 mice (Figure 2c ). In turn, activation of p38 MAPK is essential in regulating the resistance of Wip1-deficient mice to mammary gland tumors driven by ErbB2 oncogene (Bulavin et al., 2004) . However, activation of MKK6 does not result in a phenotype that closely resembles the breast tumorresistant phenotype of Wip1-deficient mice: MMTV-MKK6/ErbB2 mice show only a tendency to delay tumor onset compared to MMTV-ErbB2 females (Figure 2c ). One possible reason is the fact that activation of MKK6/p38 MAPK results in upregulation of Wip1 phosphatase (Takekawa et al., 2000; Figures 2d and 3c) . This subsequently could either inactivate molecules downstream of MKK6 such as p38 MAPK, thus weakening the effect of MKK6, or shut down other signaling pathways, such as the ATM/Chk2-dependent tumor-suppressor cascade (Figure 3c ). We cannot also exclude the possibility that the presence of constitutively active MKK6 is not sufficient to fully activate p38 MAPK-dependent responses in breast epithelium and may require additional activation by MKK3. MKK3, along with MKK6, is a potent regulator of p38 MAPK that plays an important role in suppressing tumorigenesis as oncogene-expressing Mkk3/Mkk6-double null cells grow into larger tumors than wild-type cells when explanted into nude mice (Brancho et al., 2003) . Thus, it would be of interest to know whether a simultaneous It remains to be determined whether there is an oncogene within the 17q23 breast cancer amplicon whose overexpression could drive tumorigenesis in transgenic mice. The 17q23 amplification occurs fairly frequently (B18%) in primary human breast cancers (Kallioniemi et al., 1994; Sinclair et al., 2003) and there are three potential oncogenes, RPS6KB1, TBX-2 and WIP1, which have been identified within this genomic locus (Sinclair et al., 2003) . However, overexpression of either WIP1, Tbx2 or both in MMTVtransgenic mice is not sufficient for tumor formation (present study and data not shown). This raises the possibility that the remaining RPS6KB1 gene is a critical oncogene within the 17q23 tumor amplicon or that amplification (and overexpression) of all genes within this region is required to drive breast cancer. Alternatively, the 17q23 amplicon could provide a selective advantage for expanding a clonal variant of cancer cells. In such a scenario, the genes within this region would not have to be initiating oncogenes in transgenic models but would need certain initiating events to have a selective advantage.
In summary, we show that despite the profound tumor-resistant phenotype of Wip1-deficient mice (Bulavin et al., 2004) , Wip1 phosphatase is a weak oncogene in vivo that can promote tumorigenesis only in cooperation with other oncogenes, such as ErbB2. This tumorpromoting effect of Wip1 can be fully abrogated by activation of the MKK6/p38 MAPK signaling pathway, indicating that there is an interdependence between these two signaling pathways in the regulation of mammary gland tumorigenesis.
